RY10-4, a novel anti-tumor compound, exhibited its anti-angiogenesis activity by down-regulation of the HIF-1α and inhibition phosphorylation of AKT and mTOR

Cancer Chemotherapy and Pharmacology
Ziwei LiuJinlan Ruan

Abstract

To assess the anti-angiogenesis potential and mechanism of RY10-4, a derivative of protoapigenone, which was verified the broad-spectrum anti-tumor activities by previous study. RY10-4 and RY10-3 were synthesized according to the procedure described. Breast cancer cells MCF-7 and MDA-MB-231 that got the best performance in the previous anti-tumor activity screening were selected for further anti-cancer mechanism research. Firstly, cells proliferation assay of RY10-4 and RY10-3 was used to demonstrate the fact that the 4-hydroxy-2,5-cyclohexadien-1-one system would be the efficient pharmacophore of RY10-4. Then, a series of assays such as human umbilical vein endothelial cells (HUVECs) proliferation assay, HUVECs migration, tube network formation and morphological observations of zebrafish were applied to confirm its anti-angiogenesis activity. Upon RY10-4 treatment, the HIF-1α and VEGF were analyzed by western blot in normoxic and hypoxic conditions, meanwhile the PI3K-AKT-mTOR pathway-related protein such as AKT, p-AKT, mTOR and p-mTOR was also analyzed. In the MCF-7, MDA-MB-231 and HUVECs proliferation assay, RY10-4 that has 4-hydroxy-2,5-cyclohexadien-1-one system showed distinct advantage compared with RY10-3. Tests had ver...Continue Reading

References

Jan 3, 1990·Journal of the National Cancer Institute·J Folkman
Jan 1, 1982·Cancer Chemotherapy and Pharmacology·H J Senn
Mar 5, 1996·Proceedings of the National Academy of Sciences of the United States of America·S ParangiD Hanahan
Jun 1, 1996·Cancer Metastasis Reviews·K P Claffey, G S Robinson
May 1, 1997·Lancet·A L Harris
May 23, 2000·Critical Reviews in Biochemistry and Molecular Biology·G L Semenza
Aug 16, 2001·Proceedings of the National Academy of Sciences of the United States of America·M S NeshatC L Sawyers
Nov 26, 2003·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Mohammad Atiqur Rahman, Masakazu Toi
May 4, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G Taraboletti, R Giavazzi
Oct 12, 2004·Biochemical and Biophysical Research Communications·Xiao-Song ZhongBing-Hua Jiang
May 4, 2005·Cancer Research·Tracey D BradshawMalcolm F G Stevens
Mar 21, 2007·Cancer Chemotherapy and Pharmacology·R Longo, G Gasparini
Jul 12, 2007·Journal of Medicinal Chemistry·An-Shen LinKuo-Hsiung Lee
Aug 26, 2009·Biochimie·Bogdan ManolescuCornelia Cercasov
Apr 13, 2010·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·X H HuangJ L Ruan
Jul 12, 2011·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Anhua WeiJinlan Ruan
Jul 22, 2011·The Breast : Official Journal of the European Society of Mastology·Susumu ShibasakiMasato Takahashi
Dec 17, 2011·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Dong LiuZhaocong Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

© 2021 Meta ULC. All rights reserved